File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.jneuroim.2022.577952
- Scopus: eid_2-s2.0-85136463176
- WOS: WOS:000855690900001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Meningoencephalitis in primary antibody deficiency: Our experience from northwest India
Title | Meningoencephalitis in primary antibody deficiency: Our experience from northwest India |
---|---|
Authors | |
Keywords | Common Variable Immunodeficiency Enterovirus Intravenous immunoglobulin Meningoencephalitis Primary antibody deficiency X-linked agammaglobulinemia |
Issue Date | 8-Aug-2022 |
Publisher | Elsevier |
Citation | Journal of Neuroimmunology, 2022, v. 371 How to Cite? |
Abstract | Background/Objectives: Patients with primary antibody deficiency (PAD) are predisposed to develop meningoencephalitis, often considered to be enteroviral. However, there is a paucity of literature on this subject, and there are no studies from developing countries. Methods: We analyzed our cohort of children with PAD who developed meningoencephalitis.Results: This complication was observed in 13/135 (10.4%) patients with PAD - 5 patients had X-linked agammaglobulinemia (XLA), 7 had common variable immunodeficiency (CVID) and 1 had suspected nuclear factor kappa B essential modulator (NEMO) defect. Mean age at onset of neurological illness was 9.3 years. Presenting features included seizures (n=8), neurodevelopmental delay (n=2), regression of milestones (n=2), and acute flaccid paralysis (n=1). Trough IgG levels were found to be low in 12/13 patients at the time of development of neurological symptoms. Herpes simplex virus (HSV), cytomegalovirus (CMV), and Streptococcus pneumoniae were isolated in 1 each. Eight (72.7%) patients had altered signal hyperintensities in gray matter and deep white matter on magnetic resonance imaging (MRI), while 4 patients showed global cerebral atrophy. All patients were treated with high-dose intravenous immunoglobulin (IVIg). Fluoxetine was given to 3 patients. Eight patients in the present series have died, 3 have recovered with varying degrees of neurological sequelae and 2 patients are showing gradual recovery. |
Persistent Identifier | http://hdl.handle.net/10722/331433 |
ISSN | 2023 Impact Factor: 2.9 2023 SCImago Journal Rankings: 0.897 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jindal, AK | - |
dc.contributor.author | Chaudhary, H | - |
dc.contributor.author | Tyagi, R | - |
dc.contributor.author | Rawat, A | - |
dc.contributor.author | Suri, D | - |
dc.contributor.author | Patra, PK | - |
dc.contributor.author | Arora, K | - |
dc.contributor.author | Chawla, S | - |
dc.contributor.author | Vyas, S | - |
dc.contributor.author | Arora, M | - |
dc.contributor.author | Aggarwal, R | - |
dc.contributor.author | Basu, S | - |
dc.contributor.author | Bansal, R | - |
dc.contributor.author | Sachdeva, MUS | - |
dc.contributor.author | Gupta, A | - |
dc.contributor.author | Pandiarajan, V | - |
dc.contributor.author | Sankhyan, N | - |
dc.contributor.author | Suthar, R | - |
dc.contributor.author | Sahu, JK | - |
dc.contributor.author | Singh, M | - |
dc.contributor.author | Mani, R | - |
dc.contributor.author | Sharma, R | - |
dc.contributor.author | Saka, R | - |
dc.contributor.author | Imai, K | - |
dc.contributor.author | Ohara, O | - |
dc.contributor.author | Nonoyama, S | - |
dc.contributor.author | Hammarstrom, L | - |
dc.contributor.author | Chan, KW | - |
dc.contributor.author | Lau, YL | - |
dc.contributor.author | Singh, S | - |
dc.date.accessioned | 2023-09-21T06:55:41Z | - |
dc.date.available | 2023-09-21T06:55:41Z | - |
dc.date.issued | 2022-08-08 | - |
dc.identifier.citation | Journal of Neuroimmunology, 2022, v. 371 | - |
dc.identifier.issn | 0165-5728 | - |
dc.identifier.uri | http://hdl.handle.net/10722/331433 | - |
dc.description.abstract | <p></p><p>Background/Objectives: Patients with primary antibody deficiency (PAD) are predisposed to develop meningoencephalitis, often considered to be enteroviral. However, there is a paucity of literature on this subject, and there are no studies from developing countries. Methods: We analyzed our cohort of children with PAD who developed meningoencephalitis.Results: This complication was observed in 13/135 (10.4%) patients with PAD - 5 patients had X-linked agammaglobulinemia (XLA), 7 had common variable immunodeficiency (CVID) and 1 had suspected nuclear factor kappa B essential modulator (NEMO) defect. Mean age at onset of neurological illness was 9.3 years. Presenting features included seizures (n=8), neurodevelopmental delay (n=2), regression of milestones (n=2), and acute flaccid paralysis (n=1). Trough IgG levels were found to be low in 12/13 patients at the time of development of neurological symptoms. Herpes simplex virus (HSV), cytomegalovirus (CMV), and Streptococcus pneumoniae were isolated in 1 each. Eight (72.7%) patients had altered signal hyperintensities in gray matter and deep white matter on magnetic resonance imaging (MRI), while 4 patients showed global cerebral atrophy. All patients were treated with high-dose intravenous immunoglobulin (IVIg). Fluoxetine was given to 3 patients. Eight patients in the present series have died, 3 have recovered with varying degrees of neurological sequelae and 2 patients are showing gradual recovery.<br></p> | - |
dc.language | eng | - |
dc.publisher | Elsevier | - |
dc.relation.ispartof | Journal of Neuroimmunology | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Common Variable Immunodeficiency | - |
dc.subject | Enterovirus | - |
dc.subject | Intravenous immunoglobulin | - |
dc.subject | Meningoencephalitis | - |
dc.subject | Primary antibody deficiency | - |
dc.subject | X-linked agammaglobulinemia | - |
dc.title | Meningoencephalitis in primary antibody deficiency: Our experience from northwest India | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.jneuroim.2022.577952 | - |
dc.identifier.scopus | eid_2-s2.0-85136463176 | - |
dc.identifier.volume | 371 | - |
dc.identifier.isi | WOS:000855690900001 | - |
dc.identifier.issnl | 0165-5728 | - |